Expertise in
7
conditions

Dr. Tarah J. Ballinger

Internal Medicine
IU Health Simon Cancer Center
1030 W Michigan St, 
Indianapolis, IN 
Accepting New Patients
Expertise in
7
conditions
IU Health Simon Cancer Center
1030 W Michigan St, 
Indianapolis, IN 

Overview

Tarah Ballinger is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana.

Dr. Ballinger is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Li-Fraumeni Syndrome, and Hormone Replacement Therapy (HRT).

She is actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 11 clinical trials. Dr. Ballinger is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in IN

Hospital Affiliations

Indiana University Health
Iu Health West Hospital
Indiana University Health North Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 11 Less Insurance Carriers -

Locations

IU Health Simon Cancer Center
1030 W Michigan St, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
Enrollment Status: Completed
Publish Date: May 28, 2026
Intervention Type: Device
Study Phase: Not Applicable
20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)
20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Combination product, Drug
Study Drugs: Pertuzumab+Trastuzumab, Adjuvant Endocrine Therapy
Study Phase: Phase 2
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer
A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Neratinib, Fulvestrant
Study Phase: Phase 2
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Other, Drug
Study Drugs: atezolizumab, carboplatin
Study Phase: Phase 2
Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study
Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study
Enrollment Status: Withdrawn
Publish Date: December 15, 2022
Intervention Type: Drug, Procedure
Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer
Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer
Enrollment Status: Completed
Publish Date: October 14, 2021
Intervention Type: Procedure
View 9 Less Clinical Trials

61 Total Publications

NCCN Guidelines® Insights: Survivorship, Version 3.2026.
NCCN Guidelines® Insights: Survivorship, Version 3.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 17, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Michael W. Weiner
Internal Medicine
Expertise in
12
conditions
Dr. Michael W. Weiner
Internal Medicine

Richard L. Roudebush Veterans Affairs Medical Center

1481 W 10th St, 
Indianapolis, IN 
 (0.5 miles away)
317-554-0000
Languages Spoken:
English
See accepted insurances

Michael Weiner is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana. Dr. Weiner is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Developmental Dysphasia Familial, and Post-Traumatic Stress Disorder (PTSD).

Expertise in
13
conditions
Dr. Lee W. Mchenry
Internal Medicine
Expertise in
13
conditions
Dr. Lee W. Mchenry
Internal Medicine

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (0.1 miles away)
317-944-0980
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lee Mchenry is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana. Dr. Mchenry is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Biliary Dyskinesia, Sphincter of Oddi Dysfunction, Chronic Pancreatitis, Endoscopy, and Pancreaticoduodenectomy. Dr. Mchenry is currently accepting new patients.

Expertise in
3
conditions
Dr. Dawn M. Bravata
Internal Medicine
Expertise in
3
conditions
Dr. Dawn M. Bravata
Internal Medicine

Richard L. Roudebush Veterans Affairs Medical Center

1481 W 10th St, 
Indianapolis, IN 
 (0.5 miles away)
317-554-0000
Languages Spoken:
English
See accepted insurances

Dawn Bravata is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana. Dr. Bravata is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Transient Ischemic Attack (TIA), Stroke, Hypertension, Severe Acute Respiratory Syndrome (SARS), and Carotid Artery Surgery.

Frequently Asked Questions about Dr. Tarah J. Ballinger

How do I make an appointment with Dr. Tarah J. Ballinger?

You can book an appointment with Dr. Tarah J. Ballinger by calling their office at 317-948-6260. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tarah J. Ballinger a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tarah J. Ballinger is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tarah J. Ballinger specialize in?

While Dr. Tarah J. Ballinger is a Internal Medicine, they have specific expertise in Breast Cancer, Triple-Negative Breast Cancer, and HER-2 Positive Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Tarah J. Ballinger participate in research or clinical trials?

Yes. Dr. Tarah J. Ballinger has published 61 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Tarah J. Ballinger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tarah J. Ballinger accept my insurance?

Dr. Tarah J. Ballinger accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-948-6260 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ballinger's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile